URAT1&XO inhibitor 2

URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia[1].

Product Specifications

CAS Number

[1239488-96-0]

UNSPSC

12352005

Target

URAT1; Xanthine Oxidase

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/urat1-xo-inhibitor-2.html

Concentration

10mM

Purity

98.69

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

BrC(C=C1)=CC=C1C/C(C2=C(C=C(C=C2)O)O)=N\O

Molecular Formula

C14H12BrNO3

Molecular Weight

322.15

References & Citations

[1]Hu Q, et al. (E) -2- (4-bromophenyl) -1- (2, 4-dihydroxyphenyl) ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1. Biomed Pharmacother. 2017 Feb;86:88-94.